母嬰健康治療市場規模、佔有率和成長分析：按產品類型、適應症、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球母嬰健康市場價值為 119.2 億美元，預計到 2025 年將成長至 129.3 億美元，到 2033 年將成長至 248.4 億美元，在預測期（2026-2033 年）內複合年成長率為 8.5%。

全球孕產婦健康市場涵蓋藥品、生技藥品和醫療設備，旨在解決妊娠毒血症、妊娠糖尿病和產後出血等併發症，這些併發症對於改善母嬰結果至關重要。人們日益認知到孕產婦健康與兒童生存之間的聯繫，這推動了全球投資，市場重心也從有限的學名藥轉向靶向單株抗體和胰島素類似物等創新療法。孕產婦心理健康藥物，特別是針對周產期憂鬱症的藥物，日益受到關注，這是成長要素，並促使政府支持和醫療覆蓋部分藥物。此外，人工智慧驅動的藥物研發正在革新該領域，加速個人化療法的開發，加速臨床試驗進程，提高醫療質量，並開啟孕產婦健康創新新時代。

全球母嬰健康市場的成長要素

病患、醫護人員和政策制定者對孕產婦健康重要性的認知不斷提高，是推動先進治療方案需求的主要動力。這種認知的加深，促使人們更廣泛地接受早期診斷和創新療法，並加強研發投入，從而拓展了市場機會。加強相關人員的教育，提高了新療法的接受度，並加速了其在各個地區的推廣應用。此外，隨著公共衛生宣傳活動強調孕產婦健康的重要性，家庭在尋求醫療保健方面也更加積極主動，這進一步提升了對安全有效療法的需求，並推動了市場成長。

全球母嬰保健藥品市場限制因素

全球母嬰保健療法市場面臨許多挑戰，阻礙其發展。許多農村地區缺乏專業的母嬰保健服務，限制了先進療法的普及。此外，醫療基礎設施不足、訓練有素的專業人員短缺以及交通途徑不便，阻礙了及時診斷和治療，從而抑制了市場滲透。這些障礙對生產商的分銷帶來困難，導致產品普及率降低，並對整體成長潛力產生負面影響。解決這些區域差異需要投資於當地設施和人力資源發展。此外，患者因費用問題而猶豫不決，也進一步減緩了新療法的推廣應用。

全球母嬰保健藥品市場趨勢

全球孕產婦健康市場正經歷著變革性的趨勢，而數位化產前監測技術的融合正是推動這一趨勢的關鍵因素。穿戴式感測器和行動醫療平台的興起，透過為孕婦和臨床醫生提供血壓、胎心率等即時生理數據，正在革新產前護理。這種能力不僅有助於及早發現潛在併發症，還能透過雲端分析實現的先進風險評估，進而促進個人化照護。此外，遠距醫療的普及也提高了孕產婦獲得基本醫療服務的機會，尤其惠及了服務不足的人群，進而催生了對符合遠距監測方案的標靶治療日益成長的需求。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球母嬰健康治療市場規模：依產品類型分類

• 製藥
  • 孕婦維生素和補充劑
  • 抗感染藥物
  • 荷爾蒙療法
  • 抗高血壓藥物
  • 其他
• 生物製藥

全球母嬰保健藥物市場規模：依適應症分類

• 早產
• 妊娠毒血症和子癇
• 妊娠糖尿病
• 孕婦和產後婦女的感染疾病
• 產後出血
• 其他

全球母嬰保健藥物市場規模：依給藥途徑分類

• 口服
• 注射藥物
• 外用
• 其他

全球母嬰保健藥品市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球母嬰保健藥品市場規模：依最終用戶分類

• 醫院
• 婦產科診所
• 門診手術中心
• 家庭醫療保健

全球母嬰健康治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Sanofi SA
• Novo Nordisk A/S
• Bayer AG
• Johnson & Johnson
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• AbbVie Inc.
• Eli Lilly and Company
• Amgen Inc.
• Gedeon Richter Plc.
• Organon & Co.
• Boehringer Ingelheim International GmbH
• Biogen Inc.
• Viatris Inc.
• CSL Limited
• Ferring BV

結論與建議

Global Maternal Health Therapeutics Market size was valued at USD 11.92 Billion in 2024 and is poised to grow from USD 12.93 Billion in 2025 to USD 24.84 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The Global Maternal Health Therapeutics market comprises drugs, biologics, and medical devices aimed at addressing complications such as pre-eclampsia, gestational diabetes, and postpartum hemorrhage, crucial for improving outcomes for mothers and infants. The growing recognition of the connection between maternal health and child survival fuels worldwide investments, transitioning the market from a modest focus on generic medications to innovative treatments, including targeted monoclonal antibodies and insulin analogues. The rising focus on maternal mental health therapeutics, particularly for perinatal depression, is a key growth driver, leading to governmental support and reimbursement for specific medications. Additionally, AI-driven drug discovery is revolutionizing the landscape by expediting the development of personalized therapies, enabling faster clinical trials and improved care, and fostering a new era of innovation in maternal health.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Maternal Health Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Maternal Health Therapeutics Market Segments Analysis

Global maternal health therapeutics market is segmented by product type, indication, route of administration, distribution channel, end user and region. Based on product type, the market is segmented into Pharmaceuticals and Biologics. Based on indication, the market is segmented into Preterm Labor, Preeclampsia & Eclampsia, Gestational Diabetes, Maternal Infections, Postpartum Hemorrhage and Other Maternal Conditions. Based on route of administration, the market is segmented into Oral, Injectable, Topical and Other Routes. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Maternity Clinics, Ambulatory Surgical Centers and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Maternal Health Therapeutics Market

The rising awareness regarding the significance of maternal health among patients, healthcare professionals, and policymakers is a major driving force behind the demand for advanced therapeutic solutions. This increased understanding leads to earlier diagnoses and a greater openness to innovative treatments, as well as heightened investment in research and development, thereby broadening the market opportunities. Efforts by stakeholders to enhance educational initiatives foster a wider acceptance of novel therapies, promoting their adoption in various regions. Additionally, as public health campaigns highlight the advantages of maternal well-being, families become more proactive in pursuing healthcare, further boosting the demand for safe and effective therapeutic options, which strengthens market growth.

Restraints in the Global Maternal Health Therapeutics Market

The Global Maternal Health Therapeutics market faces significant challenges that impede its growth. Access to specialized maternal health services is limited in many rural areas, restricting the availability of advanced therapeutics. Furthermore, inadequate healthcare infrastructure, a lack of trained professionals, and transportation issues hinder timely diagnosis and treatment, stifling market penetration. These barriers create distribution difficulties for manufacturers and result in lower adoption rates, adversely affecting overall growth potential. Investing in local facilities and workforce development is essential to address these geographic disparities. Additionally, patient hesitancy related to cost concerns further slows the uptake of new therapies.

Market Trends of the Global Maternal Health Therapeutics Market

The Global Maternal Health Therapeutics market is witnessing a transformative trend driven by the integration of digital prenatal monitoring technologies. The rise of wearable sensors and mobile health platforms is revolutionizing antenatal care by providing expectant mothers and clinicians with real-time physiological data, such as blood pressure and fetal heart rate. This capability not only facilitates early detection of potential complications but also promotes personalized care through advanced risk profiling enabled by cloud-based analytics. Furthermore, the expansion of tele-consultations is broadening access to essential maternal health care, particularly for underserved populations, thereby amplifying the demand for targeted therapeutic regimens that align with remote monitoring protocols.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Maternal Health Therapeutics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Pharmaceuticals
  • Prenatal Vitamins & Supplements
  • Anti-Infectives
  • Hormonal Therapies
  • Antihypertensives
  • Other Pharmaceuticals
• Biologics

Global Maternal Health Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Preterm Labor
• Preeclampsia & Eclampsia
• Gestational Diabetes
• Maternal Infections
• Postpartum Hemorrhage
• Other Maternal Conditions

Global Maternal Health Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical
• Other Routes

Global Maternal Health Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Maternal Health Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Maternity Clinics
• Ambulatory Surgical Centers
• Home Healthcare

Global Maternal Health Therapeutics Market Size & CAGR (2026-2033)

• North America (Product Type, Indication, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Product Type, Indication, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations